Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
click here now to get all the chilling details.
Jonathan Alspaugh net worth and biography

Jonathan Alspaugh Biography and Net Worth

Jonathan Alspaugh has over a decade of experience advising healthcare companies on strategic and financial matters. Jonathan joined Aeglea from Evercore where he most recently served as a managing director in the firm’s corporate advisory business. At Evercore, Jonathan was involved in numerous strategic transactions including advising Bristol-Myers Squibb on its acquisition of Celgene, Akebia on its merger with Keryx, PTC Therapeutics on its acquisition of Emflaza, and dozens of successful equity financings to support the strategic growth of clients in the biopharma space. Prior to Evercore, Jonathan was a member of Barclays Capital’s global healthcare investment banking team. Previously, Jonathan served in the United States Marine Corps infantry. Jonathan received an S.M. from the Harvard-MIT Division of Health Sciences and Technology, an M.B.A. from the Massachusetts Institute of Technology Sloan School of Management and a B.S.E. and an M.S.E. in Nuclear Engineering and Radiological Sciences from the University of Michigan.

How do I contact Jonathan Alspaugh?

The corporate mailing address for Mr. Alspaugh and other Aeglea BioTherapeutics executives is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. Aeglea BioTherapeutics can also be reached via phone at (512) 942-2935 and via email at [email protected] Learn More on Jonathan Alspaugh's contact information.

Has Jonathan Alspaugh been buying or selling shares of Aeglea BioTherapeutics?

Jonathan Alspaugh has not been actively trading shares of Aeglea BioTherapeutics during the past quarter. Most recently, on Friday, March 11th, Jonathan Alspaugh bought 75,000 shares of Aeglea BioTherapeutics stock. The stock was acquired at an average cost of $2.08 per share, with a total value of $156,000.00. Learn More on Jonathan Alspaugh's trading history.

Who are Aeglea BioTherapeutics' active insiders?

Aeglea BioTherapeutics' insider roster includes Jonathan Alspaugh (CFO), Anthony Quinn (CEO), and Armen Shanafelt (Director). Learn More on Aeglea BioTherapeutics' active insiders.

Are insiders buying or selling shares of Aeglea BioTherapeutics?

During the last year, Aeglea BioTherapeutics insiders bought shares 6 times. They purchased a total of 375,528 shares worth more than $615,668.44. The most recent insider tranaction occured on August, 25th when Director Marcio Souza bought 90,000 shares worth more than $50,400.00. Insiders at Aeglea BioTherapeutics own 6.5% of the company. Learn More about insider trades at Aeglea BioTherapeutics.

Information on this page was last updated on 8/25/2022.

Jonathan Alspaugh Insider Trading History at Aeglea BioTherapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/11/2022Buy75,000$2.08$156,000.00View SEC Filing Icon  
12/9/2021Buy50,000$3.72$186,000.00View SEC Filing Icon  
8/18/2021Buy7,200$6.72$48,384.00View SEC Filing Icon  
8/16/2021Buy9,780$6.37$62,298.60View SEC Filing Icon  
See Full Table

Jonathan Alspaugh Buying and Selling Activity at Aeglea BioTherapeutics

This chart shows Jonathan Alspaugh's buying and selling at Aeglea BioTherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aeglea BioTherapeutics Company Overview

Aeglea BioTherapeutics logo
Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
Read More

Today's Range

Now: $0.51
Low: $0.48
High: $0.52

50 Day Range

MA: $0.56
Low: $0.35
High: $1.27

2 Week Range

Now: $0.51
Low: $0.34
High: $4.54


290,155 shs

Average Volume

399,862 shs

Market Capitalization

$31.37 million

P/E Ratio


Dividend Yield



Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
click here now to get all the chilling details.